Popular Trials
Monoclonal Antibodies
MEDI6570 for Heart Attack
Recruiting0 awardsPhase 2
Decatur, GA
This trial is testing MEDI6570, a new medication that aims to reduce inflammation in people who have had a heart attack. The goal is to see if it can help prevent more heart problems. The study will help decide how to use this medication in future treatments.
Dupilumab for Ulcerative Colitis
Recruiting0 awardsPhase 2
Roswell, Georgia
This trial tests dupilumab, a medication that reduces inflammation, in people with moderate to severe Ulcerative Colitis who have a specific type of immune response. The goal is to see if it can help reduce their symptoms by blocking proteins that cause inflammation.
Monoclonal Antibodies
SGN-2FF for Breast Cancer
Recruiting1 awardPhase 1
Atlanta, Georgia
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF. This study will also attempt to find the most suitable dose in the disease or condition being studied and look at other effects of SGN2FF, including its effect on cancer. This study has several different parts. Part A will try to find the highest safe dose. Part B will enroll more patients to be treated at the highest safe dose or a lower dose to better understand how well SGN-2FF is tolerated. Part C will try to find the highest safe dose of SGN-2FF when it is given combined with pembrolizumab. Pembrolizumab is a standard treatment for cancer. Part D will enroll more patients to be treated at the highest safe dose of SGN-2FF combined with pembrolizumab or a lower dose of SGN-2FF to better understand how well SGN-2FF is tolerated when it is given with pembrolizumab.
Alkylating agents
Cisplatin +2 More for Throat Cancer
Recruiting1 awardPhase 1
Atlanta, Georgia
This phase I trial studies the side effects and best dose of pembrolizumab when given together with cisplatin and intensity-modulated radiation therapy, in treating patients with stage III-IV squamous cell carcinoma of the head and neck. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Intensity-modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab with cisplatin and intensity-modulated radiation therapy may work better in treating patients with squamous cell carcinoma of the head and neck.
Tyrosine Kinase Inhibitor
Erlotinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Popular Filters
Phase 3 Trials
Selective Serotonin Reuptake Inhibitor (SSRI)
Fluoxetine +1 More for Depression
Recruiting3 awardsPhase 3
Atlanta, Georgia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone compared with placebo in pediatric outpatients (7-17 years of age) with major depressive disorder.
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
Recruiting3 awardsPhase 3
Atlanta, Georgia
This trial will study the long-term effects of dupilumab, a drug used to treat atopic dermatitis, in adults. The trial will also assess the immunogenicity of dupilumab and monitor its efficacy. There is also an optional sub-study that will assess the safety of a new dupilumab drug product and evaluate its systemic exposure and immunogenicity.
Antiretroviral
E/C/F/TAF +1 More for Antiretroviral Therapy
Recruiting3 awardsPhase 3
Atlanta, Georgia
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
Trials With No Placebo
Monoclonal Antibodies
Dupilumab for Atopic Dermatitis
Recruiting3 awardsPhase 3
Atlanta, Georgia
This trial will study the long-term effects of dupilumab, a drug used to treat atopic dermatitis, in adults. The trial will also assess the immunogenicity of dupilumab and monitor its efficacy. There is also an optional sub-study that will assess the safety of a new dupilumab drug product and evaluate its systemic exposure and immunogenicity.
Immunomodulatory Agent
Lenalidomide + Dexamethasone +/- Thalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Atlanta, Georgia
This trial tests if lenalidomide with either standard or low-dose dexamethasone works better for new multiple myeloma patients. If not, thalidomide is added. The goal is to find effective treatments with fewer side effects. Lenalidomide plus low-dose dexamethasone has been shown to be an effective treatment for multiple myeloma, particularly in patients who are not candidates for stem cell transplantation.
Corticosteroid
Dexamethasone +2 More for Multiple Myeloma
Recruiting4 awardsPhase 3
Lawrenceville, Georgia
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
AZD9977 +1 More for Chronic Kidney Disease
Recruiting1 awardPhase 2
Eatonton, Georgia
This trial tests a new drug, AZD9977, combined with dapagliflozin in patients with heart failure and chronic kidney disease. The goal is to see if this combination improves kidney function and heart health better than using dapagliflozin alone. Dapagliflozin is a medication that has been shown to reduce heart-related deaths and heart failure in patients with chronic heart failure.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.